BR9809055A - 5,7-disubstituted 4-amino-pyrido (2,3-d) pyrimidine compounds and their use as adenosinokinase inhibitors - Google Patents
5,7-disubstituted 4-amino-pyrido (2,3-d) pyrimidine compounds and their use as adenosinokinase inhibitorsInfo
- Publication number
- BR9809055A BR9809055A BR9809055-0A BR9809055A BR9809055A BR 9809055 A BR9809055 A BR 9809055A BR 9809055 A BR9809055 A BR 9809055A BR 9809055 A BR9809055 A BR 9809055A
- Authority
- BR
- Brazil
- Prior art keywords
- alkyl
- aryl
- heteroaryl
- heterocyclic
- compounds
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title abstract 2
- -1 5,7-disubstituted 4-amino-pyrido (2,3-d) pyrimidine compounds Chemical class 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 6
- 125000000217 alkyl group Chemical group 0.000 abstract 3
- 125000003710 aryl alkyl group Chemical group 0.000 abstract 3
- 125000001072 heteroaryl group Chemical group 0.000 abstract 3
- 125000000623 heterocyclic group Chemical group 0.000 abstract 3
- 241000124008 Mammalia Species 0.000 abstract 2
- 125000003342 alkenyl group Chemical group 0.000 abstract 2
- 125000000304 alkynyl group Chemical group 0.000 abstract 2
- 125000003118 aryl group Chemical group 0.000 abstract 2
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 2
- 125000004446 heteroarylalkyl group Chemical group 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 229910052757 nitrogen Inorganic materials 0.000 abstract 2
- 201000006474 Brain Ischemia Diseases 0.000 abstract 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 abstract 1
- 206010008120 Cerebral ischaemia Diseases 0.000 abstract 1
- 206010061218 Inflammation Diseases 0.000 abstract 1
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 abstract 1
- 206010040047 Sepsis Diseases 0.000 abstract 1
- 229910052799 carbon Inorganic materials 0.000 abstract 1
- 206010008118 cerebral infarction Diseases 0.000 abstract 1
- 206010015037 epilepsy Diseases 0.000 abstract 1
- 125000005842 heteroatom Chemical group 0.000 abstract 1
- 125000000592 heterocycloalkyl group Chemical group 0.000 abstract 1
- 230000004054 inflammatory process Effects 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 abstract 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 abstract 1
- 229910052760 oxygen Inorganic materials 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 239000000546 pharmaceutical excipient Substances 0.000 abstract 1
- 229940124531 pharmaceutical excipient Drugs 0.000 abstract 1
- 229910052717 sulfur Inorganic materials 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Rheumatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Pain & Pain Management (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Urology & Nephrology (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
"COMPOSTOS DE 4-AMINO--PIRIDO[2,3-d]PIRIMIDINA 5,7-DISSUBSTITUìDA E SEU USO COMO INIBIDORES DE ADENOSINOCINASE" Método para inibir adenosinocinase administrando um composto que tem a fórmula (I) onde R^ 1^ e R^ 2^ são independentemente selecionados entre H, alquila inferior, alcóxi (C~ 1~-C~ 6~)-alquila (C~ 1~-C~ 6~), aril-alquila (C~ 1~-C~ 6~), -C(O)-alquila (C~ 1~-C~ 6~), -C(O)-arila, -C(O)-heterocíclico, ou podem unir-se ao nitrogênio ao qual eles estão anexados, para formar um anel de 5 a 7 membros, contendo opcionalmente 1 a 2 heteroátomos adicionais, selecionados entre O, N ou S; R^ 3^ é selecionado em grupo consistindo de alquila inferior, alquenila inferior, alquinila inferior, ciclo-alquila, arila, aril-alquila, heteroarila, grupo heterocíclico, heteroaril-alquila ou heterociclo-alquila, em que os grupos heteroarila e heterocíclico estão ligados diretamente ou indiretamente por um carbono anelar; R^ 4^ é selecionado em grupo consistindo de alquila inferior, alquenila inferior, alquinila inferior, ciclo-alquila, arila, aril-alquila, heteroarila, grupo heterocíclico, heteroaril-alquila ou heterociclo-alquila; e uma linha tracejada - - - indica que uma dupla ligação está opcionalmente presente, desde que as valências apropriadas sejam mantidas, uma composição farmacêutica que compreende uma quantidade terapeuticamente eficaz de um desses compostos acima em combinação com um excipiente de uso farmacêutico, e um método para tratar isquemia cerebral, epilepsia, nicipercepção, inflamação e sepse em um mamífero que necessite desse tratamento, que compreende administrar ao mamífero uma quantidade terapeuticamente eficaz de um composto desses, um processo para preparar esses compostos, e compostos que têm a fórmula acima na qual R^ 1^, R^ 2^, R^ 3^ e R^ 4^ são definidos separadamente."4-AMINO COMPOUNDS - PIRID [2,3-d] PYRIMIDIN 5,7-DISSUBSTITUED AND THEIR USE AS ADENOSINOCINASE INHIBITORS" Method to inhibit adenosinokinase by administering a compound that has the formula (I) where R ^ 1 ^ e R ^ 2 ^ are independently selected from H, lower alkyl, (C ~ 1 ~ -C ~ 6 ~) -alkyl (C ~ 1 ~ -C ~ 6 ~), aryl-alkyl (C ~ 1 ~ -C ~ 6 ~), -C (O) -alkyl (C ~ 1 ~ -C ~ 6 ~), -C (O) -aryl, -C (O) -heterocyclic, or they can bond with the nitrogen to which they are attached, to form a 5- to 7-membered ring, optionally containing 1 to 2 additional heteroatoms, selected from O, N or S; R ^ 3 ^ is selected from the group consisting of lower alkyl, lower alkenyl, lower alkynyl, cycloalkyl, aryl, aryl-alkyl, heteroaryl, heterocyclic group, heteroaryl-alkyl or heterocycle-alkyl, in which the heteroaryl and heterocyclic groups are linked directly or indirectly by an annular carbon; R 4 is selected from the group consisting of lower alkyl, lower alkenyl, lower alkynyl, cycloalkyl, aryl, aryl-alkyl, heteroaryl, heterocyclic, heteroaryl-alkyl or heterocyclo-alkyl; and a dotted line - - - indicates that a double bond is optionally present, provided that the appropriate valencies are maintained, a pharmaceutical composition comprising a therapeutically effective amount of one of these compounds above in combination with a pharmaceutical excipient, and a method to treat cerebral ischemia, epilepsy, niciperception, inflammation and sepsis in a mammal in need of such treatment, which comprises administering to the mammal a therapeutically effective amount of such a compound, a process for preparing those compounds, and compounds having the above formula in which R ^ 1 ^, R ^ 2 ^, R ^ 3 ^ and R ^ 4 ^ are defined separately.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US83821697A | 1997-04-16 | 1997-04-16 | |
| PCT/US1998/007207 WO1998046605A1 (en) | 1997-04-16 | 1998-04-14 | 5,7-disubstituted 4-aminopyrido[2,3-d]pyrimidine compounds and their use as adenosine kinase inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR9809055A true BR9809055A (en) | 2000-08-08 |
Family
ID=25276561
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR9809055-0A BR9809055A (en) | 1997-04-16 | 1998-04-14 | 5,7-disubstituted 4-amino-pyrido (2,3-d) pyrimidine compounds and their use as adenosinokinase inhibitors |
Country Status (18)
| Country | Link |
|---|---|
| EP (1) | EP0989986A1 (en) |
| JP (1) | JP2001520655A (en) |
| KR (1) | KR20010006509A (en) |
| CN (1) | CN1252070A (en) |
| AR (1) | AR012436A1 (en) |
| AU (1) | AU7108398A (en) |
| BG (1) | BG103842A (en) |
| BR (1) | BR9809055A (en) |
| CA (1) | CA2286909A1 (en) |
| CO (1) | CO4940446A1 (en) |
| HU (1) | HUP0001434A3 (en) |
| IL (1) | IL131618A0 (en) |
| NO (1) | NO995036L (en) |
| PL (1) | PL336304A1 (en) |
| SK (1) | SK141799A3 (en) |
| TR (1) | TR199902455T2 (en) |
| WO (1) | WO1998046605A1 (en) |
| ZA (1) | ZA983177B (en) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2000023444A1 (en) * | 1998-10-21 | 2000-04-27 | Abbott Laboratories | 5,7-disubstituted-4-aminopyrido[2,3-d]pyrimidine compounds |
| ATE305303T1 (en) | 2001-02-12 | 2005-10-15 | Hoffmann La Roche | 6-SUBSTITUTED PYRIDOPYRIMIDINES |
| CA2473796A1 (en) | 2002-01-17 | 2003-07-31 | Neurogen Corporation | Substituted quinazolin-4-ylamine analogues |
| DE10335183A1 (en) * | 2003-07-30 | 2005-02-24 | Bayer Cropscience Ag | Fungicidal drug combinations |
| MX2008000885A (en) * | 2005-07-21 | 2008-03-18 | Hoffmann La Roche | PYRIDO [2 , 3-D] PYRIMIDINE-2 , 4-DIAMINE COMPOUNDS AS PTPlB INHIBITORS. |
| WO2007081517A2 (en) | 2005-12-21 | 2007-07-19 | Abbott Laboratories | Anti-viral compounds |
| ES2378473T3 (en) * | 2005-12-21 | 2012-04-12 | Abbott Laboratories | Antiviral compounds |
| EP2094276A4 (en) | 2006-12-20 | 2011-01-05 | Abbott Lab | Anti-viral compounds |
| EP2182809B1 (en) | 2007-08-27 | 2018-01-17 | Dart Neuroscience (Cayman) Ltd | Therapeutic isoxazole compounds |
| EP2181992B8 (en) | 2007-08-31 | 2013-06-26 | Eisai R&D Management Co., Ltd. | Polycyclic compound |
| DE102007061764A1 (en) * | 2007-12-20 | 2009-06-25 | Bayer Healthcare Ag | Anellated cyanopyridines and their use |
| SG173710A1 (en) * | 2009-02-26 | 2011-09-29 | Eisai R&D Man Co Ltd | Nitrogen-containing fused heterocyclic compounds and their use as beta amyloid production inhibitors |
| JP6496246B2 (en) | 2012-10-05 | 2019-04-03 | メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． | Indoline compounds as related to aldosterone synthase inhibitors |
| KR102375929B1 (en) | 2016-03-31 | 2022-03-16 | 온크터널 테라퓨틱스, 인코포레이티드. | Indoline analogs and uses thereof |
| CN110256420B (en) * | 2019-05-07 | 2020-04-28 | 江西中医药大学 | Tetrahydropyridopyrimidine derivatives and preparation methods and uses thereof |
| CN110283171A (en) * | 2019-07-17 | 2019-09-27 | 鼎泰(南京)临床医学研究有限公司 | Compound of the one kind containing Pyridopyrimidine -4- amine structure, pharmaceutical composition and its application |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5324731A (en) * | 1989-02-14 | 1994-06-28 | Amira, Inc. | Method of inhibiting transformation of cells in which purine metabolic enzyme activity is elevated |
| IL112249A (en) * | 1994-01-25 | 2001-11-25 | Warner Lambert Co | Pharmaceutical compositions containing di and tricyclic pyrimidine derivatives for inhibiting tyrosine kinases of the epidermal growth factor receptor family and some new such compounds |
| US6143749A (en) * | 1995-06-07 | 2000-11-07 | Abbott Laboratories | Heterocyclic substituted cyclopentane compounds |
-
1998
- 1998-04-14 HU HU0001434A patent/HUP0001434A3/en unknown
- 1998-04-14 CN CN98804151A patent/CN1252070A/en active Pending
- 1998-04-14 KR KR1019997009599A patent/KR20010006509A/en not_active Withdrawn
- 1998-04-14 SK SK1417-99A patent/SK141799A3/en unknown
- 1998-04-14 AU AU71083/98A patent/AU7108398A/en not_active Abandoned
- 1998-04-14 PL PL98336304A patent/PL336304A1/en unknown
- 1998-04-14 WO PCT/US1998/007207 patent/WO1998046605A1/en not_active Ceased
- 1998-04-14 JP JP54408898A patent/JP2001520655A/en active Pending
- 1998-04-14 EP EP98918093A patent/EP0989986A1/en not_active Withdrawn
- 1998-04-14 BR BR9809055-0A patent/BR9809055A/en not_active Application Discontinuation
- 1998-04-14 IL IL13161898A patent/IL131618A0/en unknown
- 1998-04-14 TR TR1999/02455T patent/TR199902455T2/en unknown
- 1998-04-14 CA CA002286909A patent/CA2286909A1/en not_active Abandoned
- 1998-04-15 AR ARP980101733A patent/AR012436A1/en unknown
- 1998-04-15 ZA ZA983177A patent/ZA983177B/en unknown
- 1998-04-16 CO CO98020979A patent/CO4940446A1/en unknown
-
1999
- 1999-10-15 NO NO995036A patent/NO995036L/en not_active Application Discontinuation
- 1999-10-29 BG BG103842A patent/BG103842A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO1998046605A1 (en) | 1998-10-22 |
| AU7108398A (en) | 1998-11-11 |
| KR20010006509A (en) | 2001-01-26 |
| EP0989986A1 (en) | 2000-04-05 |
| PL336304A1 (en) | 2000-06-19 |
| JP2001520655A (en) | 2001-10-30 |
| CO4940446A1 (en) | 2000-07-24 |
| BG103842A (en) | 2000-06-30 |
| CN1252070A (en) | 2000-05-03 |
| TR199902455T2 (en) | 2000-01-21 |
| NO995036D0 (en) | 1999-10-15 |
| CA2286909A1 (en) | 1998-10-22 |
| NO995036L (en) | 1999-10-15 |
| AR012436A1 (en) | 2000-10-18 |
| HUP0001434A3 (en) | 2001-01-29 |
| HUP0001434A2 (en) | 2000-10-28 |
| SK141799A3 (en) | 2000-08-14 |
| ZA983177B (en) | 1999-01-22 |
| IL131618A0 (en) | 2001-01-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR9809055A (en) | 5,7-disubstituted 4-amino-pyrido (2,3-d) pyrimidine compounds and their use as adenosinokinase inhibitors | |
| UY25993A1 (en) | PROCEDURE TO PREPARE DERIVATIVES OF HYDROXY ACID-HYDROXAMIC PIPECOLATE | |
| BR0109109A (en) | Compound, use thereof, process for preparing it, pharmaceutical composition, and method of treating a ccr5-mediated disease state in mammals | |
| BRPI0517423A (en) | compound, pharmaceutical composition, method for treating or preventing neurological and psychiatric disorders associated with glutamate dysfunction in an animal, and, use in a compound | |
| EP1807412A1 (en) | Cyclic diarly ureas suitable as tyrosine kinase inhibitors | |
| RU94039542A (en) | Derivatives of piperazine as 5-ht-receptor antagonists, method of synthesis, pharmaceutical composition | |
| BR9808254A (en) | Compounds, use and process for their preparation, pharmaceutical composition, and, process for treating depression, anxiety, parkinson's disease, obesity, cognitive disorders, sudden illnesses, neurological and neuroprotective disorders to protect against conditions such as stroke in human beings. | |
| BRPI0410477A (en) | compound or a pharmaceutically acceptable salt thereof, method for the prophylaxis or treatment of a chiral condition in a mammal, pharmaceutical formulation, combination, use of a compound, and process for preparing a compound | |
| ES2131207T3 (en) | AMIDAS DERIVATIVES OF VALPROIC ACID AND 2-VALPROENOIC ACID AND ITS USE AS ANTICONVULSIVES. | |
| EA200100764A1 (en) | TRICYCLIC INHIBITORS POLY (ADP-RIBOZO) POLYMERASE | |
| NZ504482A (en) | Aryl fused azapolycyclic compounds and pharmaceuticals thereof which bind to neuronal nicotinic acetylcholine specific recpetor sites and are useful for modulating cholinergic function | |
| CA2386297A1 (en) | Bicyclic amino acids as pharmaceutical agents | |
| BR0108694A (en) | Malnic acid derivatives, process for preparing them, use of them as an inhibitor of factor xa activity and pharmaceutical compositions containing the same | |
| ATE181329T1 (en) | SUBSTITUTED DIBENZOOXAZEPINE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE | |
| AR026974A1 (en) | N- [5 - [[[5-ALQUIL-2-OXAZOLIL] METHYL] UNCLE] -2-TIAZOLIL] -CARBOXAMIDS, USEFUL AS INHIBITORS OF CYCLINE-DEPENDENT KINASES, AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | |
| RU94036761A (en) | Derivatives of galanthamine and pharmaceutical composition | |
| ATE152352T1 (en) | PHARMACEUTICAL COMPOSITIONS FOR INHIBITING THE MAILLARD REACTION | |
| BRPI0315958B8 (en) | compound, pharmaceutical composition, process for preparing a compound, new intermediates and use of the compound | |
| ES2063998T3 (en) | USE OF N-ALKYL 1,4-DIHYDROPYRIDIN-DICARBOXYL ACID ESTERS AS MEDICATIONS, NEW COMPOUNDS AND PROCEDURE FOR THEIR PREPARATION. | |
| ATE202551T1 (en) | LIGNANS, PROCESS FOR THEIR PRODUCTION, THEIR PHARMACEUTICAL COMPOSITIONS AND APPLICATIONS | |
| MXPA04000779A (en) | Substituted-aryl 7-aza[2.2.1]bicycloheptanes for the treatment of disease. | |
| BR0211030A (en) | Pyrrolidine oxadiazole derivative, use of a pyrrolidine oxadiazole derivative, pharmaceutical composition containing at least one pyrrolidine oxadiazole derivative, method for preparing a pyrrolidine oxadiazole compound | |
| ATE244221T1 (en) | PYRROLE DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME | |
| BRPI0607701A2 (en) | compound or a pharmaceutically acceptable salt, ester, solvate, stereoisomer, tautomer or prodrug thereof, pharmaceutical composition, use of an antibacterially effective amount of a compound together with a pharmaceutically acceptable carrier, and method of preparing a compound | |
| BR9809088A (en) | 6,7-di-substituted-4-aminopyrido [2,3-d] pyrimidine compounds |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA10 | Dismissal: dismissal - article 33 of industrial property law | ||
| B11Y | Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette] |